Trametinib, a selective MEK inhibitor, has demonstrated preclinical efficacy against RAS-mutant, MLL-rearranged ALL within specific microenvironmental niches, where it effectively reduces ERK phosphorylation in vivo [36, 37]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.